This is a working overview of Lactam bridge, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-06-28. Anything still debated is marked as such rather than presented as settled.
Receptor activation in hypothalamic and limbic circuits is the mechanism most often cited for the observed effects on sexual desire. Signalling through MC4R couples to Gs proteins and raises intracellular cyclic AMP, which in turn modulates dopaminergic tone in reward-related pathways. Because the peptide reaches the central nervous system after subcutaneous administration, peripheral vascular changes are regarded as secondary rather than primary. The precise neural circuits that translate receptor occupancy into behavioural change remain incompletely mapped, and published accounts describe the pathway in general terms rather than as a fully resolved sequence.
Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.
Approved use is narrow and jurisdiction-specific. In the United States, the injectable product is authorised for premenopausal women with acquired, generalised hypoactive sexual desire disorder, a diagnosis that requires documented distress. It is not approved for men, for postmenopausal women, or for use alongside hormonal contraceptives under the approved labelling. Outside regulated markets, the same peptide is frequently sold as a research chemical, where identity, purity, and sterility are not independently verified.
Bremelanotide is a synthetic cyclic heptapeptide developed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and appetite signalling. Its structure contains seven amino acid residues joined by a lactam bridge that closes the ring between two side chains. The molecular formula is C50H68N14O10 and the nominal molecular mass is near 1025 daltons. Much of the early laboratory literature refers to the same molecule by the development code PT-141.
The compound emerged from a research programme examining melanocortin analogues for effects on skin pigmentation. During early human studies, participants reported spontaneous erections as an unexpected side effect, which redirected development toward sexual function rather than tanning. An intranasal formulation was investigated in clinical trials but did not reach market approval. A subcutaneous injectable version later completed the regulatory process, and the nasal route does not appear in approved labelling.
| Property | Value | Notes |
|---|---|---|
| Research code | PT-141 | Used in early literature before the generic name became common |
| Generic name | Bremelanotide | International nonproprietary name |
| Peptide class | Cyclic heptapeptide | Seven residues joined by a lactam bridge |
| Primary receptor | MC4R | Lower affinity reported at MC1R, MC3R and MC5R |
| Route studied clinically | Subcutaneous injection | Intranasal route was abandoned after pressor effects |
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.
Bremelanotide is a moderately large peptide with a molecular mass near 1025 daltons. In lyophilised form it appears as a white to off-white powder and is freely soluble in water and other polar solvents. The intact lactam ring is essential for receptor affinity, while linearised fragments bind far more weakly. Solutions are sensitive to extremes of pH and to prolonged exposure to light and heat, so handling typically involves buffered conditions and cold storage. Its short plasma half-life reflects rapid distribution and clearance rather than chemical breakdown inside the vial.
left splicing junction Also donor splicing junction or donor splicing site. The boundary between the left end (by convention, the 5' end) of an intron and the right (3') end of an adjacent exon in a pre-mRNA transcript.
Sanger changed his research project to study the metabolism of lysine and a more practical problem concerning the nitrogen of potatoes. His thesis had the title, "The metabolism of the amino acid lysine in the animal body". He was examined by Charles Harington and Albert Charles Chibnall and awarded his doctorate in 1943.
Andress, Jason. Winterfeld, Steve. (2011). Cyber Warfare: Techniques, Tactics and Tools for Security Practitioners. Syngress. ISBN 1-59749-637-5 Bodmer, Kilger, Carpenter, & Jones (2012). Reverse Deception: Organized Cyber Threat Counter-Exploitation. New York: McGraw-Hill Osborne Media. ISBN 0-07-177249-9, "ISBN 978-0-07-177249-5" Brenner, S. (2009). Cyber Threats: The Emerging Fault Lines of the Nation State. Oxford University Press. ISBN 0-19-538501-2 Carr, Jeffrey. (2010). Inside Cyber Warfare: Mapping the Cyber Underworld. O'Reilly. ISBN 978-0-596-80215-8 Conti, Gregory. Raymond, David. (2017). On Cyber: Towards an Operational Art for Cyber Conflict. Kopidion Press. ISBN 978-0-692-91156-3 Cordesman, Anthony H.; Cordesman, Justin G. (2002). Cyber-threats, Information Warfare, and Critical Infrastructure Protection: Defending the U.S. Homeland. Greenwood Publishing Group. ISBN 978-0-275-97423-7. Costigan, Sean S.; Perry, Jake (2012). Cyberspaces and global affairs. Farnham, Surrey: Ashgate. ISBN 978-1-4094-2754-4. Fritsch, Lothar & Fischer-Hübner, Simone (2019). Implications of Privacy & Security Research for the Upcoming Battlefield of Things. Journal of Information Warfare, 17(4), 72–87. Gaycken, Sandro. (2012). Cyberwar – Das Wettrüsten hat längst begonnen. Goldmann/Randomhouse. ISBN 978-3-442-15710-5 Geers, Kenneth. (2011). Strategic Cyber Security. NATO Cyber Centre.
=== Sa–Sc === Margarita Salas (1938–2019). Spanish biochemist at the Spanish National Research Council. Known for work on DNA replication. First woman elected to the Royal Spanish Academy. Wolfram Saenger (1939–2026). German biochemist and protein crystallographer at the Free University of Berlin, known for work on membrane proteins and protein-nucleic acid complexes. Member Natl. Acad. Sci. USA Frederick Sanger FRS (1918–2013). British biochemist at Cambridge University, known for advances in sequencing proteins and nucleic acids. Nobel prizes in Chemistry (1958, 1980). Foreign Associate Natl. Acad. Sci. USA. Albert Schatz (1920–2005). American microbiologist and science educator at Temple University, the discoverer of the antibiotic streptomycin. Paul Schimmel (b. 1940). American biochemist at the Scripps Research Institute, who developed methods of nucleic acid sequencing and coauthored (with Charles Cantor) the very influential three-volume book Biophysical Chemistry. Member Natl. Acad. Sci. USA Rudolph Schoenheimer (1898–1941). German-American biochemist at Columbia, pioneer of radioactive tagging of molecules. Stefan Schuster (b. 1961). German biophysicist at the University of Jena, pioneer in metabolic control analysis and metabolic pathway analysis. Rose Scott-Moncrieff (1903–1991). British biochemical geneticist at the University of Cambridge.
An accompanying study showed that the artificial WW domains were functionally similar to natural WW domains in ligand binding affinity and specificity. In de novo protein structure prediction, it has been shown that, when combined with a simple residue-residue distance metric, SCA-based scoring can fairly accurately distinguish native from non-native protein folds.
Sources: en.wikipedia.org
=== Australia === Across most of the continent, El Niño and La Niña have more impact on climate variability than any other factor. There is a strong correlation between the strength of La Niña and rainfall: the greater the sea surface temperature and Southern Oscillation difference from normal, the larger the rainfall change. During El Niño events, the shift in rainfall away from the Western Pacific may mean that rainfall across Australia is reduced. Over the southern part of the continent, warmer than average temperatures can be recorded as weather systems are more mobile and fewer blocking areas of high pressure occur. The onset of the Indo-Australian Monsoon in tropical Australia is delayed by two to six weeks, which as a consequence means that rainfall is reduced over the northern tropics. The risk of a significant bushfire season in south-eastern Australia is higher following an El Niño event, especially when it is combined with a positive Indian Ocean Dipole event.
Weak affinity chromatography (WAC) is an affinity chromatography technique for affinity screening in drug development. WAC is an affinity-based liquid chromatographic technique that separates chemical compounds based on their different weak affinities to an immobilized target. The higher affinity a compound has towards the target, the longer it remains in the separation unit, and this will be expressed as a longer retention time. The affinity measure and ranking of affinity can be achieved by processing the obtained retention times of analyzed compounds. Affinity chromatography is part of a larger suite of techniques used in chemoproteomics based drug target identification. The WAC technology is demonstrated against a number of different protein targets – proteases, kinases, chaperones and protein–protein interaction (PPI) targets. WAC has been shown to be more effective than established methods for fragment based screening. Affinity chromatography was conceived and first developed by Pedro Cuatrecasas and Meir Wilchek.
The calculation uses 8,033 years, the mean-life derived from Libby's half-life of 5,568 years, not 8,267 years, the mean-life derived from the more accurate modern value of 5,730 years. Libby's value for the half-life is used to maintain consistency with early radiocarbon testing results; calibration curves include a correction for this, so the accuracy of final reported calendar ages is not affected.
Regulatory agencies, such as the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA), have established approval pathways to ensure biosimilar insulins meet the same quality, safety, and efficacy standards as reference products.
Sources: en.wikipedia.org
== Titanium dioxide and zinc oxide nanoparticles in sunscreen == Sunscreens are utilized to secure the skin from the destructive impacts of ultraviolet radiation from the sun. UVB (290-320 nm) together with UVA-2 (320–340 nm) and UVA-1 (340–400 nm) cause organic and metabolic reactions in the skin. Titanium dioxide (TiO2) and zinc oxide (ZnO) minerals are often utilized in sunscreens as inorganic physical sun blockers owing to their absorption of light in the UV range. As TiO2 is proven to be more effective for blocking UVB and ZnO in the UVA range, the mix of these particles guarantees a broad-band UV shield. To solve the cosmetic disadvantage of these opaque sunscreens, TiO2 and ZnO nanoparticles have been used as a replacement for TiO2 and ZnO microparticles. Since the surface area to volume proportion of particles increases as the particle measurement diminishes, nanoparticles (NPs), ie, nano objects with all dimensions in the nanoscale, might be increasingly (bio)reactive than typical mass materials. When particles become smaller than 100 nm, novel optical attributes develop, owing to discrete nature of nanoparticle optical energy levels. Pat et al., for instance, measured a 0.15 eV blue shift for 4.7 nm TiO2 nanoparticles relative to the bulk material counterpart. When particles become smaller than the ideal light dispersing size (roughly half of the wavelength) visible light is transmitted and the particles appear transparent. This phenomenon explains the cosmetically undesired opaqueness of inorganic sunscreens and makes the utilization of NPs monetarily appealing.
1956: 1956 Summer Olympics – USSR-Hungary Blood in the Water match following the Hungarian Revolution and the Soviet invasion of Hungary 1969: 1969 World Ice Hockey Championships – USSR-Czechoslovakia following the 1968 Soviet invasion of Czechoslovakia 1972: 1972 Summer Olympics – The USSR defeats the United States in men's basketball in a controversial gold medal game 1972: Canada–USSR Summit Series – Canada defeats the Soviet Union in this best-on-best eight-game series 1972: 1972 World Chess Championship Fischer (USA) – Spassky (USSR) – Bobby Fischer beats Spassky in this championship held in Reykjavik, Iceland 1980: Miracle on Ice – The United States upsets the favoured USSR at the 1980 Winter Olympics 1980: 1980 Summer Olympics boycott – by the United States 1984: 1984 Summer Olympics boycott – by the Soviet Union
=== Reactivity === Metallic elements which are more electropositive than hydrogen, particularly the alkali metals and, to a lesser extent, alkaline earth metals, displace hydrogen from water, forming hydroxides and releasing hydrogen. At high temperatures, coke, a form of carbon, reacts with steam to form carbon monoxide and hydrogen.
Sources: en.wikipedia.org
The code designates bremelanotide, a cyclic heptapeptide melanocortin receptor agonist. It served as an internal research identifier before the compound entered formal clinical development. The code and the generic name refer to the same molecule.
MC4R is generally described as the principal target, based on binding affinity and functional assays. Activity at MC1R, MC3R and MC5R is reported as weaker. Receptor selectivity is one reason the compound was pursued for central rather than vascular effects.
Both are synthetic melanocortin analogues built on a similar cyclic peptide scaffold. Bremelanotide is described in the literature as a metabolite-derived analogue of melanotan II rather than the same substance. The two differ in terminal modifications, which affect half-life and receptor profile.
It is a synthetic cyclic peptide that acts as an agonist at melanocortin receptors. It is not a hormone replacement therapy and not a vasodilator in the usual clinical sense, although it does affect vascular tone. Chemically it belongs to the melanocortin analogue family.